norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Journal of Hepatology

Volumn 67, Issue 3, 2017, Pages 549-558

  Fickert, Peter ^a   Hirschfield, Gideon M ^b   Denk, Gerald ^c   Marschall, Hanns Ulrich ^d   Altorjay, Istvan ^e   Färkkilä, Martti ^f   Schramm, Christoph ^g   Spengler, Ulrich ^h   Chapman, Roger ⁱ   Bergquist, Annika ^j   Schrumpf, Erik ^k   Nevens, Frederik ^l   Trivedi, Palak ^b   Reiter, Florian P ^c   Tornai, Istvan ^e   Halilbasic, Emina ^m   Greinwald, Roland ⁿ   Pröls, Markus ⁿ   Manns, Michael P ^o   Trauner, Michael ^m  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f UNIVERSITY OF HELSINKI   (Finland)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY OF BONN   (Germany)

ⁱ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁿ Dr Falk Pharma GmbH   (Germany)

^o HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Alkaline phosphatase; Bile acid treatment; Cholehepatic shunting; Cholestasis; Sclerosing cholangitis; Side chain shortened bile acids; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID; 24-NORURSODEOXYCHOLIC ACID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CHOLESTASIS; COLON CANCER; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHINOPHARYNGITIS; SIDE EFFECT; SPLENOMEGALY; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; SCLEROSING CHOLANGITIS;

ADULT; ALKALINE PHOSPHATASE; CHOLANGITIS, SCLEROSING; CHOLESTASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; URSODEOXYCHOLIC ACID;

EID: 85020856876     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.05.009     Document Type: Article

References (44)

1. Hirschfield, G.M., Karlsen, T.H., Lindor, K.D., Adams, D.H., Primary sclerosing cholangitis. Lancet 382 (2013), 1587–1599.
2. Williamson, K.D., Chapman, R.W., New therapeutic strategies for primary sclerosing cholangitis. Semin Liver Dis 36 (2016), 5–14.
3. Karlsen, T.H., Vesterhus, M., Boberg, K.M., Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther 39 (2014), 282–301.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51 (2009), 237–267.
5. Lindor, K.D., Kowdley, K.V., Harrison, M.E., American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 110 (2015), 646–659 [Quiz 660].
6. Chazouillères, O., Poupon, R., Capron, J.P., Metman, E.H., Dhumeaux, D., Amouretti, M., et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 11 (1990), 120–123.
7. O'Brien, C.B., Senior, J.R., Arora-Mirchandani, R., Batta, A.K., Salen, G., Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14 (1991), 838–847.
8. Beuers, U., Spengler, U., Kruis, W., Aydemir, U., Wiebecke, B., Heldwein, W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16 (1992), 707–714.
9. Lindor, K.D., Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336 (1997), 691–695.
10. Olsson, R., Boberg, K.M., de Muckadell, O.S., Lindgren, S., Hultcrantz, R., Folvik, G., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129 (2005), 1464–1472.
11. Lindor, K.D., Kowdley, K.V., Luketic, V.A., Harrison, M.E., McCashland, T., Befeler, A.S., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50 (2009), 808–814.
12. Wunsch, E., Trottier, J., Milkiewicz, M., Raszeja-Wyszomirska, J., Hirschfield, G.M., Barbier, O., et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 60 (2014), 931–940.
13. Fickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127 (2004), 261–274.
14. Fickert, P., Wagner, M., Marschall, H.U., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130 (2006), 465–481.
15. Halilbasic, E., Fiorotto, R., Fickert, P., Marschall, H.U., Moustafa, T., Spirli, C., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 49 (2009), 1972–1981.
16. Moustafa, T., Fickert, P., Magnes, C., Guelly, C., Thueringer, A., Frank, S., et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 142 (2012), 140–151 e12.
17. Sombetzki, M., Fuchs, C.D., Fickert, P., Österreicher, C.H., Mueller, M., Claudel, T., et al. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol 62 (2015), 871–878.
18. Hofmann, A.F., Zakko, S.F., Lira, M., Clerici, C., Hagey, L.R., Lambert, K.K., et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42 (2005), 1391–1398.
19. Cohen, B.I., Hofmann, A.F., Mosbach, E.H., Stenger, R.J., Rothschild, M.A., Hagey, L.R., et al. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology 91 (1986), 189–197.
20. Hofmann, A.F., Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49 (2009), 1403–1418.
21. Hofmann, A.F., Hagey, L.R., Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65 (2008), 2461–2483.
22. Beuers, U., Hohenester, S., de Buy Wenniger, L.J., Kremer, A.E., Jansen, P.L., Elferink, R.P., The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52 (2010), 1489–1496.
23. Beuers, U., Trauner, M., Jansen, P., Poupon, R., New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62 (2015), S25–S37.
24. Jacoby, A., Rannard, A., Buck, D., Bhala, N., Newton, J.L., James, O.F., et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 54 (2005), 1622–1629.
25. Hanauer, S., Schwartz, J., Robinson, M., Roufail, W., Arora, S., Cello, J., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial, Pentasa Study Group. Am J Gastroenterol 88 (1993), 1188–1197.
26. Humphreville, V.R., Radosevich, D.M., Humar, A., Payne, W.D., Kandaswamy, R., Lake, J.R., et al. Longterm health-related quality of life after living liver donation. Liver Transpl 22 (2016), 53–62.
27. Stanich, P.P., Björnsson, E., Gossard, A.A., Enders, F., Jorgensen, R., Lindor, K.D., Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 43 (2011), 309–313.
28. Al Mamari, S., Djordjevic, J., Halliday, J.S., Chapman, R.W., Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 58 (2013), 329–334.
29. Ponsioen, C.Y., Chapman, R.W., Chazouillères, O., Hirschfield, G.M., Karlsen, T.H., Lohse, A.W., et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology 63 (2016), 1357–1367.
30. Lehmacher, W., Wassmer, G., Adaptive sample size calculations in group sequential trials. Biometrics 55 (1999), 1286–1290.
31. Hommel, G., A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75 (1988), 383–386.
32. Koenig, G., Seneff, S., Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers, 2015, 2015, 818570.
33. Yamada, J., Tomiyama, H., Yambe, M., Koji, Y., Motobe, K., Shiina, K., et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis 189 (2006), 198–205.
34. Park, W.Y., Koh, E.S., Kim, S.H., Kim, Y.O., Jin, D.C., Song, H.C., et al. Serum gamma-glutamyltransferase levels predict clinical outcomes in hemodialysis patients. PLoS One, 10, 2015, e0138159.
35. Ehlken, H., Wroblewski, R., Corpechot, C., Arrivé, L., Lezius, S., Hartl, J., et al. Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut 65 (2016), 1230–1232.
36. de Vries, E.M., Wang, J., Leeflang, M.M., Boonstra, K., Weersma, R.K., Beuers, U., et al. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and one year later: evaluation of prognostic value. Liver Int, 2016.
37. Rupp, C., Rössler, A., Halilbasic, E., Sauer, P., Weiss, K.H., Friedrich, K., et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther 40 (2014), 1292–1301.
38. Lindström, L., Hultcrantz, R., Boberg, K.M., Friis-Liby, I., Bergquist, A., Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 11 (2013), 841–846.
39. Jansen, P.L., Ghallab, A., Vartak, N., Reif, R., et al. The ascending pathophysiology of cholestatic liver disease. Hepatology 65 (2016), 722–738.
40. Hirschfield, G.M., Mason, A., Luketic, V., Lindor, K., Gordon, S.C., Mayo, M., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148 (2015), 751–761 e8.
41. Lieu, T., Jayaweera, G., Zhao, P., Poole, D.P., Jensen, D., Grace, M., et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 147 (2014), 1417–1428.
42. Kremer, A.E., Namer, B., Bolier, R., Fischer, M.J., Oude Elferink, R.P., Beuers, U., Pathogenesis and management of pruritus in PBC and PSC. Dig Dis 33 (2015), 164–175.
43. Vesterhus, M., Hov, J.R., Holm, A., Schrumpf, E., Nygård, S., Godang, K., et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology 62 (2015), 188–197.
44. de Vries, E.M., Verheij, J., Hubscher, S.G., Leeflang, M.M., Boonstra, K., Beuers, U., et al. Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. J Hepatol 63 (2015), 1212–1219.